Literature DB >> 27497694

Standardization of administered activities in paediatric nuclear medicine: the EANM perspective.

Michael Lassmann1, Uta Eberlein1, Egesta Lopci2, Arturo Chiti3,4.   

Abstract

Mesh：

Year:  2016        PMID： 27497694     DOI： 10.1007/s00259-016-3474-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  10 in total

1.  Recommended administered activities for (68)Ga-labelled peptides in paediatric nuclear medicine.

Authors:  J Soares Machado; S Beykan; K Herrmann; M Lassmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-09       Impact factor: 9.236

2.  Optimised tracer-dependent dosage cards to obtain weight-independent effective doses.

Authors:  F Jacobs; H Thierens; A Piepsz; K Bacher; C Van de Wiele; H Ham; R A Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12-24       Impact factor: 9.236

3.  The new EANM paediatric dosage card.

Authors:  M Lassmann; L Biassoni; M Monsieurs; C Franzius; F Jacobs
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-04       Impact factor: 9.236

4.  The new EANM paediatric dosage card: additional notes with respect to F-18.

Authors:  M Lassmann; L Biassoni; M Monsieurs; C Franzius
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-24       Impact factor: 9.236

5.  Paediatric radiopharmaceutical administration: harmonization of the 2007 EANM paediatric dosage card (version 1.5.2008) and the 2010 North American consensus guidelines.

Authors:  Michael Lassmann; S Ted Treves
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-06       Impact factor: 9.236

6.  Pediatric Radiopharmaceutical Administration: harmonization of the 2007 EANM Paediatric Dosage Card (Version 1.5.2008) and the 2010 North American Consensus guideline.

Authors:  Michael Lassmann; S Ted Treves
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08       Impact factor: 9.236

7.  A radiopharmaceuticals schedule for imaging in paediatrics. Paediatric Task Group European Association Nuclear Medicine.

Authors:  A Piepsz; K Hahn; I Roca; G Ciofetta; G Toth; I Gordon; J Kolinska; J Gwidlet
Journal:  Eur J Nucl Med       Date:  1990

Review 8.  Standardization of administered activities in pediatric nuclear medicine: a report of the first nuclear medicine global initiative project, part 1-statement of the issue and a review of available resources.

Authors:  Frederic H Fahey; Henry Hee-Seong Bom; Arturo Chiti; Yun Young Choi; Gang Huang; Michael Lassmann; Norman Laurin; Fernando Mut; Rodolfo Nuñez-Miller; Darin O'Keeffe; Prasanta Pradhan; Andrew M Scott; Shaoli Song; Nischal Soni; Mayuki Uchiyama; Luis Vargas
Journal:  J Nucl Med       Date:  2015-03-12       Impact factor: 10.057

Review 9.  Standardization of Administered Activities in Pediatric Nuclear Medicine: A Report of the First Nuclear Medicine Global Initiative Project, Part 2-Current Standards and the Path Toward Global Standardization.

Authors:  Frederic H Fahey; Henry Hee-Seung Bom; Arturo Chiti; Yun Young Choi; Gang Huang; Michael Lassmann; Norman Laurin; Fernando Mut; Rodolfo Nuñez-Miller; Darin O'Keeffe; Prasanta Pradhan; Andrew M Scott; Shaoli Song; Nischal Soni; Mayuki Uchiyama; Luis Vargas
Journal:  J Nucl Med       Date:  2016-03-31       Impact factor: 10.057

Review 10.  Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine - a review.

Authors:  Uta Eberlein; Jörn Hendrik Bröer; Charlot Vandevoorde; Paula Santos; Manuel Bardiès; Klaus Bacher; Dietmar Nosske; Michael Lassmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-30       Impact factor: 9.236
  10 in total
  1 in total

1.  Re-evaluation of pediatric 18F-FDG dosimetry: Cristy-Eckerman versus UF/NCI hybrid computational phantoms.

Authors:  Kitiwat Khamwan; Shannon E O'Reilly; Donika Plyku; Alison Goodkind; Anders Josefsson; Xinhua Cao; Frederic H Fahey; S Ted Treves; Wesley E Bolch; George Sgouros
Journal:  Phys Med Biol       Date:  2018-08-14       Impact factor: 3.609
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.